The neighborhood is already home to familiar names Samsung Biologics and Celltrion.
Just across the street, a new blue-striped Samsung Biologics building under construction – fifth on the second campus compound - stands on one side of an unfinished waterway.
Half-built roads and empty lots give little hint that this corner of Songdo is the front line of the country's contract drugmaking race.
Group Chairman Shin Dong-bin attended the completion ceremony for Plant 1 at the Lotte Biologics Songdo Bio Campus with his eldest son, Shin Yoo-yeol, the unit's co-CEO. The 120,000-liter antibody plant, begun in March 2024, runs eight 15,000-liter stainless steel bioreactors alongside smaller units. dealsite
The plant reached "GMP Ready" status this month, six months ahead of the original target, CEO James Park told reporters, meaning it is prepared to make drugs under global manufacturing and quality standards.
A day earlier, Lotte announced the plant's first large-scale commercial order, from a global drugmaker it declined to name, covering everything from clinical drug substance to finished product.
Production has begun with batches needed for regulatory approval, Chief Financial Officer Kang Hyun-shim said. Revenue will start in 2027, with commercial-scale production expected in 2028.
At full capacity, Plant 1 can generate about 700 billion won ($525.4 million) a year, Chief Growth Officer Chun Ji-won said.
With about 300 billion won from its U.S. plant, that would put Lotte near its target of more than 1 trillion won in revenue by 2030.
Syracuse is running far below capacity. It produced seven of a possible 45 batches in the first half, regulatory filings show, a 16 percent utilization rate, down from 74 percent in 2025 as BMS volumes ended. First-half revenue fell 73 percent from a year earlier to 23.9 billion won. The company said an unannounced U.S. Food and Drug Administration inspection of the site in September found no issues.
Lotte Group has put about 1.5 trillion won into the unit through seven capital increases. It plans three 120,000-liter plants in Songdo at a total cost of about 4.6 trillion won, with the timing of Plants 2 and 3 dependent on orders.
Across the water, Samsung Biologics has been building since 2011. It runs five Songdo plants with 785,000 liters of capacity, plus a 60,000-liter plant in Rockville, Maryland, bought from GSK this year, for a total of 845,000 liters. Its third-quarter revenue rose 18.5 percent from a year earlier to 1.49 trillion won.
Asked why a drugmaker would pick Lotte over its neighbor, Chun said clients often spread work across several CDMOs, matching each project to the right scale. "Once a CDMO grows past a certain level of revenue, it builds an operating framework, and that makes it less flexible for individual clients," she said. "As a latecomer, we can meet customer needs faster."
Lotte is targeting biosimilar makers, antibody-drug conjugate developers and Japanese drugmakers, Chun said, adding that Japanese firms prize long-built trust and the group can draw on its long-standing ties with Japan.
A stock market listing is not yet on the calendar. Kang said an IPO needs a clear rationale and that its timing will depend on future orders and the product pipeline. "We are heading toward making that dream come true," Chief Business Officer Park Min-soo said in English when asked about investor interest.
The waterway between the two campuses is still under construction. The 685,000-liter gap in their total capacity will take longer to close.
Copyright ⓒ Aju Press All rights reserved.

